```html

Zika‑related Guillain‑Barré Syndrome (GBS)

Overview

Guillain‑Barré syndrome (GBS) is an acute, immune‑mediated neuropathy that leads to rapid muscle weakness and, in severe cases, paralysis. When the syndrome follows infection with the Zika virus (ZIKV), it is referred to as Zika‑related GBS. The condition is rare but can be life‑threatening, especially in regions experiencing Zika outbreaks.

Who it affects

• Adults of any age, but most cases are reported in the 30‑50 year age group.
• Both sexes are equally susceptible, though some series show a slight male predominance (≈55 %).
• Pregnant women are at higher risk for Zika infection itself; data on GBS risk during pregnancy are limited.

Prevalence

• In the 2015‑2016 Zika epidemic in the Americas, the incidence of GBS rose from a baseline of ~1.1/100,000 population/year to 2.2‑2.9/100,000 in affected areas, representing a 2‑3‑fold increase (CDC, 2017).
• In French‑Polynesia (2013‑2014), a study reported 42 cases of GBS per 100,000 Zika infections—a markedly higher risk than for other arboviruses (Cao‑Lormeau et al., 2016).

Symptoms

Symptoms usually appear 3‑12 days after the onset of Zika fever, but can be delayed up to 4 weeks. The clinical picture mirrors classic GBS, with a few features reported more frequently after Zika infection.

Motor symptoms

• Ascending weakness: Starts in the feet and hands, progressing upward; can involve facial and respiratory muscles.
• Paralysis: May become generalized (quadriplegia) within days.
• Difficulty walking or climbing stairs.

Sensory symptoms

• Tingling or “pins‑and‑needles” in the feet and hands (paresthesia).
• Mild loss of vibration or proprioception.

Autonomic dysfunction

• Fluctuating blood pressure or heart rate.
• Urinary retention or constipation.
• Excessive sweating or dry skin.

Facial and cranial nerve involvement

• Facial weakness (often bilateral).
• Difficulty swallowing (dysphagia) or speaking (dysarthria).
• Eye movement abnormalities.

Respiratory symptoms

• Shortness of breath or shallow breathing due to diaphragmatic weakness.
• Need for mechanical ventilation in ~20‑30 % of severe cases.

Causes and Risk Factors

GBS itself is not caused by the virus directly; rather, the immune system mistakenly attacks peripheral nerves after a trigger.

Primary cause

• Zika virus infection: A flavivirus transmitted primarily by Aedes mosquitoes. The viral antigens share structural similarities with peripheral nerve gangliosides, prompting cross‑reactive antibodies (molecular mimicry).

Other infectious triggers (for context)

• Campylobacter jejuni (most common worldwide).
• Other arboviruses (Dengue, Chikungunya, West Nile).
• Mycoplasma pneumoniae, influenza, COVID‑19.

Risk factors specific to Zika‑related GBS

• Recent travel to or residence in Zika‑endemic regions (e.g., South America, Caribbean, Southeast Asia, Pacific islands).
• Confirmed Zika infection (positive PCR or IgM) within the previous 4 weeks.
• Pre‑existing autoimmune disorders (e.g., lupus) may predispose to a more vigorous immune response.
• Genetic susceptibility: Certain HLA types (e.g., HLA‑DRB1*03) have been linked to post‑Zika GBS in small cohorts.

Diagnosis

Because early treatment improves outcomes, clinicians must act quickly when GBS is suspected.

Clinical assessment

• History of recent Zika infection (rash, fever, arthralgia) and timing of neurological symptoms.
• Physical exam documenting pattern of weakness, reflex status (typically reduced or absent), and sensory changes.

Key investigations

• Drawn‑blood tests – complete blood count, inflammatory markers, and serology for Zika (RT‑PCR within 7 days of rash, IgM/IgG after 7 days). Also test for other triggers (C. jejuni, CMV, EBV).
• Lumbar puncture – classic “albuminocytologic dissociation”: elevated protein (>45 mg/dL) with normal white‑cell count.
• Electrodiagnostic studies – nerve‑conduction velocity (NCV) and electromyography (EMG) to confirm demyelinating pattern (AIDP) or axonal variants (AMAN/AMSAN).
• Imaging – MRI of the spine may show contrast enhancement of spinal nerve roots but is not required for diagnosis.

Diagnostic criteria

The Brighton Collaboration criteria (level 1‑3) are widely used for research and clinical certainty. A typical Zika‑related GBS case meets level 1: progressive weakness of ≥2 limbs, decreased or absent reflexes, and supportive CSF/electrodiagnostic findings.

Treatment Options

Therapy focuses on halting immune attack, supporting vital functions, and promoting nerve recovery.

First‑line immunotherapy

• Intravenous immunoglobulin (IVIG) – 0.4 g/kg/day for 5 days. Equivalent efficacy to plasma exchange (PE) and easier to administer in most settings.
• Plasma exchange (PE) – 4‑6 exchanges over 8‑10 days; preferred when IVIG is contraindicated (e.g., IgA deficiency).

Evidence from randomized trials shows both reduce time to walking ability by ~2‑3 weeks (Cochrane Review, 2020).

Supportive care

• Monitoring of respiratory function (vital capacity, negative inspiratory force). Intubation if VC < 20 mL/kg or rapid decline.
• Cardiovascular monitoring for autonomic instability; treat hypertension or bradycardia as needed.
• Pain control (gabapentin, pregabalin, or low‑dose opioids) for neuropathic pain.
• Physical and occupational therapy initiated early to prevent contractures.

Adjunctive measures

• Thromboprophylaxis (low‑dose enoxaparin) if immobilized.
• Hydration and electrolytes monitoring (especially potassium).
• Vaccination status review – avoid live vaccines while immunosuppressed.

Rehabilitation & long‑term care

Most patients improve over 6‑12 months; however, up to 20 % may have residual weakness. A multidisciplinary team (physiatrist, speech therapist, psychologist) is essential for optimal recovery.

Living with Zika‑related Guillain‑Barré Syndrome

Recovery can be gradual, and lifestyle adjustments are often needed.

Daily management tips

• Energy conservation: Break tasks into small steps, sit while dressing or cooking.
• Assistive devices: Use a cane, walker, or wheelchair as advised by therapy.
• Skin care: Inspect feet daily for pressure sores; keep skin clean and moisturized.
• Bladder & bowel routine: Schedule regular voiding; consider timed toileting or intermittent catheters if needed.
• Nutrition: High‑protein diet to support nerve regeneration; soft‑food diet if dysphagia persists.
• Psychological support: Join support groups, consider counseling for anxiety or depression.
• Keep a symptom diary (weakness progression, pain levels, respiratory measures) to share with your neurologist.

Follow‑up care

Schedule visits at 2 weeks, 1 month, 3 months, and then every 6 months for the first two years. Repeat nerve‑conduction studies may document recovery or identify chronic inflammatory demyelinating polyneuropathy (CIDP), a rare sequel.

Prevention

Because the trigger is Zika infection, primary prevention targets mosquito control and safe travel practices.

• Mosquito bite avoidance: Wear long sleeves/pants, use EPA‑registered DEET or picaridin repellents, and stay in air‑conditioned or screened rooms.
• Eliminate breeding sites: Remove standing water from containers, use larvicides in water features.
• Travel advisories: Check CDC travel notices before visiting endemic regions; postpone travel during active outbreaks if possible.
• Sexual transmission prevention: Zika can be spread sexually; use condoms or abstain for at least 3 months after symptom onset (or 8 weeks post‑infection for men, 8 weeks for women).
• Vaccination: No licensed Zika vaccine yet, but several candidates are in Phase III trials (2023‑2024). Stay informed about clinical trial enrollment if eligible.

Complications

If GBS is untreated or progresses rapidly, serious complications may arise.

• Respiratory failure: Leading cause of death; requires mechanical ventilation.
• Cardiovascular dysregulation: Sudden hypotension, arrhythmias, or autonomic storm.
• Deep‑vein thrombosis & pulmonary embolism: Due to prolonged immobility.
• Chronic neuropathic pain: Can persist for years and affect quality of life.
• Persistent weakness or disability: Up to 5‑10 % may remain unable to walk independently.
• Psychiatric sequelae: Depression, post‑traumatic stress, and anxiety are reported in 30‑40 % of survivors.

When to Seek Emergency Care

References

• Centers for Disease Control and Prevention. Zika Virus: Guillain‑Barré Syndrome. 2023. https://www.cdc.gov
• Mayo Clinic. Guillain‑Barré syndrome. 2022. https://www.mayoclinic.org
• World Health Organization. Zika virus and its link to neurological complications. 2021. https://www.who.int
• Cao‑Lormeau V, et al. “Zika virus, a new threat for neurologic disease—epidemiological, clinical, and immunologic aspects of Guillain‑Barré syndrome associated with Zika infection.” Nat Rev Neurol. 2016;12:331‑342.
• Hughes RA, et al. “Treatment of Guillain‑Barré syndrome: A systematic review.” Cochrane Database Syst Rev. 2020;(6):CD001446.
• Stowe RP, et al. “Epidemiology of Guillain‑Barré syndrome in the context of Zika virus infection.” Emerg Infect Dis. 201